Lenka Sadilkova

Company: SOTIO

Job title: Director of Pharmacology

Seminars:

SOT102, A Novel CLDN18.2-Targeting Antibody-Drug Conjugate With Strong Therapeutic Potential in Solid Tumors 12:00 pm

SOT102 is based on a novel proprietary CLDN18.2 specific monoclonal antibody, conjugated to PNU-159682 Evaluate how SOT102 demonstrated strong antitumor activity in mouse PDX models of gastric, pancreatic and other solid tumors, including those with low target expression Gain an update on a Phase 1/2 study in patients with gastric and pancreatic cancer that is…Read more

day: Day Two